Clinical

Dataset Information

0

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors


ABSTRACT: AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. This is a dose escalation study to identify the maximum toxicity dose (MTD) or the recommended phase 2 dose (RP2D).

DISEASE(S): Endometrial Cancer,Carcinoma,Cervical Cancer,Melanoma,Fallopian Tube Cancer,Colorectal Cancer,Non Small Cell Lung Cancer,Bladder Cancer,Endometrial Neoplasms,Gastroesophageal-junction Cancer,Anus Neoplasms,Squamous Cell Carcinoma Of Head And Neck,High Grade Serous Adenocarcinoma Of Ovary,Fallopian Tube Neoplasms,Primary Peritoneal Carcinoma,Gastric Cancer,Bile Duct Neoplasms,Bile Duct Cancer,Esophageal Cancer,Anal Cancer,Cystadenocarcinoma, Serous,Renal Cell Carcinoma,Head And Neck Squamous Cell Carcinoma,Hepatocellular Carcinoma

PROVIDER: 60064 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2008-10-10 | GSE9427 | GEO
2008-10-10 | E-GEOD-9427 | biostudies-arrayexpress
2011-11-15 | GSE21300 | GEO
2008-03-21 | GSE9388 | GEO
2024-02-15 | GSE228560 | GEO
2009-11-01 | GSE14050 | GEO
2009-10-31 | E-GEOD-14050 | biostudies-arrayexpress
| EGAD00010001926 | EGA
2012-11-05 | GSE39688 | GEO
| phs001257 | dbGaP